BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Abstract

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19-related outcomes, a finding consistent with that of the randomized trial.

Keywords

Coronavirus disease 2019 (COVID-19)Mass vaccinationVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakMedicineOutbreakInternal medicine

Affiliated Institutions

Related Publications

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Lisa A. Jackson , Evan J. Anderson , Nadine Rouphael +30 more

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further develop...

2020 New England Journal of Medicine 3382 citations

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang , Gang Zeng , Hongxing Pan +17 more

With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Scie...

2020 The Lancet Infectious Diseases 1488 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti , Katie Ewer , Parvinder K. Aley +97 more

2020 The Lancet 2590 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 15
Pages: 1412-1423
Citations: 2739
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2739

OpenAlex

Cite This

APA Style

                            
                                
                                    Noa Dagan, 
                                
                                    Noam Barda, 
                                
                                    Eldad Kepten
                                
                                et al.
                            
                            (2021). 
                            BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. 
                            New England Journal of Medicine
                            , 384
                            (15)
                            , 1412-1423.
                            https://doi.org/10.1056/nejmoa2101765
                        

Identifiers

DOI: 10.1056/nejmoa2101765